MSI-H
Clinical trials for MSI-H explained in plain language.
Never miss a new study
Get alerted when new MSI-H trials appear
Sign up with your email to follow new studies for MSI-H, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to outsmart stomach cancer
Disease control Recruiting nowThis Phase 3 trial tests whether a combination of two immunotherapy drugs (botensilimab and balstilimab) can help people with advanced stomach cancer live longer compared to standard treatment. The study includes 132 adults whose tumors have a specific genetic marker (MSI-H/dMMR)…
Matched conditions: MSI-H
Phase: PHASE3 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo aims to spare surgery for certain cancer patients
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of immunotherapy drugs (sintilimab, IBI310, and lenvatinib) can help people with non-metastatic dMMR/MSI-H stomach or colon cancers avoid radical surgery. About 34 participants will receive up to 24 weeks of treatment, and those…
Matched conditions: MSI-H
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC